Skip to main content
. 2010 Oct 20;17(12):1850–1858. doi: 10.1128/CVI.00230-10

FIG. 5.

FIG. 5.

Vaginal NV-specific IgA and IgG production following intranasal immunization with NV VLPs with or without CT or TLR ligands. Vaginal lavage samples were collected on days 0, 12, 21, 42, 56, 84, and 119 and analyzed for NV VLP-specific IgA (A) and IgG (B) by ELISAs. By day 42, all mice that received NV VLPs codelivered with or without adjuvant responded with a positive vaginal IgA antibody titer (GMT ≥ 2). None of the mice responded with a positive vaginal IgG titer (GMT ≥ 2) following a single immunization (days 12 and 21), except for the CT-treated group (1/8 mice). By day 119, 6/8 mice responded with a positive IgG titer in groups receiving NV VLP (25 μg) codelivered with CT, GARD, or R848 (10 μg), whereas groups immunized with NV VLP (25 μg) plus R848 (25 μg), NV VLP (5 μg) plus R848 (25 μg), or NV VLP alone responded with a positive titer in 4/7, 0/8, or 4/8 mice, respectively. Vaginal antigen-specific IgA and IgG were not detected (GMT < 2) in all preimmune samples (data not shown). Error bars represent the standard errors of the means. Values that were significantly different from the values for the PBS control group are shown as follows: ∧, P < 0.05; *, P < 0.01; **, P < 0.001. The horizontal thick broken line indicates the limit of detection for the assay.